Clinical Pharmacology
  • First-in-Human (First in Man)
  • SAD and MAD PK Studies
  • Healthy vs. Patient population
  • Drug Interactions
  • Cardiac Safety (e.g. TQTc study)
Special Population
  • Renal Impairment
  • Hepatic Impairment
  • Diabetes
  • Age, gender, etc.
PK/PD
  • Dose selection
  • Efficacy vs. Safety
Biopharmaceutics
  • Bioavailability/Bioequivalence (BA/BE)
  • Food Effect
  • Bioavailability/Bioequivalence (BA/BE)
  • Ascending Dose
  • QT/QTc Safety
  • PK/PD
  • Food Effect (Fed/Fasted)
  • Vaccines
  • Drug-to-Drug Interaction
  • Maximum Tolerated Dose
  • Drug Transfer
  • Single/Multiple Dose
  • Patch Testing
  • Devices
  • Hepatic impairment
  • Hepatic impairment, including, but not limited to, Hepatitis A, B, and C
  • Hepatic classifications as Child-Pugh A, Child-Pugh B, and Child-Pugh C (mild, moderate, and severe)
  • Renal Insufficiency
      • Classification as Mild, Moderate, and Severe, including Dialysis
  • Type I Diabetes
  • Type II Diabetes
  • Elderly
  • Hypertension
  • Pre/Postmenopausal
  • Obesity
  • Immunology
      • Plaque Psoriasis
      • Rheumatoid arthritis
      • Lupus
  • Cardiology/Vascular Diseases
  • Dermatology
  • Endocrinology
  • Gastroenterology
  • Hematology
  • Hepatology (Liver, Pancreatic, Gall Bladder)
  • Immunology
  • Infectious Diseases
  • Musculoskeletal
  • Nephrology
  • Neurology
  • Nutrition and Weight Loss
  • Obstetrics/Gynecology (Women’s Health)
  • Oncology
  • Ophthalmology
  • Orthopedics
  • Otolaryngology (Ear, Nose, Throat)
  • Pediatrics
  • Podiatry
  • Psychiatry/Psychology
  • Pulmonary/Respiratory Diseases
  • Rheumatology
  • Urology
  • Vaccines

Phase I services, Healthy Volunteers, Special Population

Phase I services, Healthy Volunteers, Special Population​